Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A disorder of amino acid metabolism that has its basis in the disruption of the urea cycle or an inherited hyperammonemia (any specific disease which causes an inherited increased concentration of ammonia in the blood).
No HPO annotations are available for this condition.
Hyperornithinemia-hyperammonemia-homocitrullinuria (HHH) syndrome is characterized by variable clinical presentation and age of onset ranging from the neonatal period to adulthood. Those with neonatal onset are normal for the first 24-48 hours, followed by onset of symptoms related to hyperammonemia (poor feeding, vomiting, lethargy, low temperature, rapid breathing). Those with later onset may present with chronic neurocognitive deficits and/or unexplained seizures, spasticity, acute encephalopathy secondary to hyperammonemic crisis, or chronic liver dysfunction. Neurologic findings and cognitive abilities can continue to deteriorate despite early metabolic control that prevents hyperammonemia.
Suggestive Findings Hyperornithinemia-hyperammonemia-homocitrullinuria (HHH) syndrome should be suspected in symptomatic individuals with the following age-related clinical, laboratory, and neuroimaging findings. Clinical Findings Neonatal presentation (~8% of individuals). Manifestations of hyperammonemia usually begin 24-48 hours after the start of feeding and can include lethargy, somnolence, refusal to feed, vomiting, tachypnea with respiratory alkalosis, and/or seizures. Infantile, childhood, and adolescent/adult presentation (~92% of individuals) may exhibit any of the following: • Chronic neurocognitive deficits including developmental and speech delay, ataxia, spasticity, learning disabilities, cognitive deficits, and/or unexplained seizures • Acute encephalopathy secondary to hyperammonemic crisis, which can be precipitated by infection, fasting, or injury (or occur for no apparent reason) and can manifest as lethargy, decreased appetite, nausea, vomiting, increased respiratory rate, and seizures • Chronic liver dysfunction characterized by unexplained elevation of liver enzymes (AST and ALT) with or without mild coagulopathy and with or without mild hyperammonemia. • Mild encephalopathy manifesting as disorientation, irritability, and episodic confusion with mild hyperammonemia, which is difficult to detect as it may resolve spontaneously without treatment or quickly normalize with IV solutions that include glucose . Laboratory Findings Episodic or postprandial mild to moderate hyperammonemia. Plasma ammonia concentrations at the time of diagnosis are summarized in . Note that neonates have a higher median plasma ammonia level than older affected individuals. Note: (1) In HHH syndrome the degree of hyperammonemia is usually significantly less than in other urea cycle disorders such as OTC, ASS, or CPS-I deficiency (see Urea Cycle Disorders). (2) Once an affected individual is placed on a protein-restricted diet and treated with sodium phenylbutyrate , plasma ammonia concentrations return to normal. Table 1. Plasma Ammonia Concentrations Observed in HHH Syndrome by Age of Diagnosis Plasma Ammonia Concentration in mol/L by Age of Diagnosis1
No approved treatments are currently available for urea cycle disorder or inherited hyperammonemia. The disease remains an area of unmet medical need.
Evaluations Following Initial Diagnosis To establish the extent of disease and needs of an individual diagnosed with the hyperornithinemia-hyperammonemia-homocitrullinuria (HHH) syndrome, the evaluations summarized (if not performed as part of the evaluation that led to diagnosis) are recommended. Table 4. Recommended Evaluations Following Initial Diagnosis in Individuals with Hyperornithinemia-Hyperammonemia-Homocitrullinuria (HHH) Syndrome
All surveillance of individuals with HHH syndrome should be a combined effort of the general pediatrician or adult practitioner and a metabolic team (metabolic geneticist, metabolic dietician, and social worker). Table 7. Recommended Surveillance for Individuals with Hyperornithinemia-Hyperammonemia-Homocitrullinuria (HHH) syndrome
No clinical trials have been registered for urea cycle disorder or inherited hyperammonemia.
205 publications have been identified in PubMed for urea cycle disorder or inherited hyperammonemia. Kisho has analyzed 80 by research type. Research spans Review / Meta-Analysis (46%), Epidemiology / Natural History (15%), and Diagnostic / Biomarker (14%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 37 | 46% |
Data assembled from 3 of 12 sources · Last updated Sep 18, 2026, 1:02 PM UTC
Source: GeneReviews — "Hyperornithinemia-Hyperammonemia-Homocitrullinuria Syndrome"
Neonatal (birth – 1 mo) (n=6) | Infantile (1 mo – 1 yr) (n=5) | Childhood (1 yr – 12 yrs) (n=36) | Adolescence to Adulthood (12 yrs) (n=17) | Total (n=64) |
|---|---|---|---|---|
Median | 300 | 173 | 120 | 117 |
Mean | 560 | 577 | 160 | 119 |
SD | 507 | 965 | 121 | 69 |
Range | 111-1300 | 49-2300 | 25-532 | 18-250 |
Source: GeneReviews — "Hyperornithinemia-Hyperammonemia-Homocitrullinuria Syndrome"
Most commonly, neonates with hyperammonemia and neonatal-onset HHH syndrome are initially suspected of having sepsis. See for a comprehensive algorithm for the differential diagnosis of neonatal hyperammonemia based on plasma and urine metabolites. Like other urea cycle disorders (UCDs), HHH syndrome should be included in the differential diagnosis of any individual with hyperammonemia, including women who experience hyperammonemia during or following pregnancy. The onset and severity of findings in HHH syndrome are more variable and less severe when compared to UCDs like ornithine transcarbamylase (OTC) deficiency or carbamyl phosphate synthase (CPS-I) deficiency (OMIM 237300).
Source: GeneReviews — "Hyperornithinemia-Hyperammonemia-Homocitrullinuria Syndrome"
Biomarker and diagnostic research for urea cycle disorder or inherited hyperammonemia has been reported in the published literature.
System/Concern | Evaluation | Comment |
|---|---|---|
Constitutional | Measurement of HT, WT, HC | Always consider ethnic/geographic origin as it may influence baseline HT WT. |
Neurologic | Assess cerebellar motor function (gait postural ataxia, dysmetria, dysdiadochokinesis, tremor, dysarthria, nystagmus, saccades smooth pursuit) | Use standardized scale to establish baseline for ataxia (SARA, ICARS, or BARS)1 Refer to neuromuscular clinic (OT/PT/ rehabilitation specialist) |
Musculoskeletal | Assess for skeletal involvement related to spasticity. | — |
Speech | For those w/dysarthria: speech-language evaluation | Improving speech can secondary behavior problems contribute to dietary adherence. |
Feeding | For those w/recurrent vomiting or severe dysphagia: assess nutritional status, aspiration risk. | Consider involving a gastroenterology/ nutrition/ feeding team. |
Psychiatric | Neuropsychiatric evaluation | In individuals age 12 mos: screen for problems incl sleep disturbances, ADHD, /or anxiety. |
Liver | Evaluate for evidence of hepatic dysfunction - biochemical profile US. | transaminases coagulopathy resolve after implementation of protein-restricted diet. Miscellaneous/ |
Other | Family support resources | Community or such as Parent to Parent Consultation w/clinical or metabolic geneticist, genetic counselor, metabolic dietician, /or social worker |
Source: GeneReviews — "Hyperornithinemia-Hyperammonemia-Homocitrullinuria Syndrome"
Avoid the following:
Excess dietary protein intake
Nonprescribed protein supplements such as those used to increase size of skeletal muscle during exercise regimens
Prolonged fasting during an illness or weight loss
Use of oral and intravenous steroids
Valproic acid, which induces and exacerbates hyperammonemia in urea cycle disorders
Exposure to communicable diseases
Source: GeneReviews — "Hyperornithinemia-Hyperammonemia-Homocitrullinuria Syndrome"
Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.
Source: GeneReviews — "Hyperornithinemia-Hyperammonemia-Homocitrullinuria Syndrome"
View trials for urea cycle disorder or inherited hyperammonemia
System/Concern
Evaluation |
|---|
Frequency |
|---|
Constitutional | Measure HT, WT, HC. BMI should always be included. | From time of diagnosis until adolescence; During pre-school years: follow WT, HT HC in conjunction w/PCP even when not seen in metabolic clinic. Metabolic status |
eating | Parents should be alert to subtle behavior changes which may suggest plasma concentrations of glutamine ammonia. | Incl changes in eating habits, motor skills, behavior; In children age ≤3 yrs, especially in flu season or hot/humid weather |
Development | Evaluation by developmental pediatrician to assess manage emergence of behavior issues (ADD/ADHD) | Prior to starting kindergarten; evaluate as needed. Academic |
performance3 | Neurocognitive evaluation | 1x/yr if any academic regression or behavior changes occur Neurologic |
evaluation | A detailed evaluation by neurologist especially in children w/neonatal, infantile, early school-age onset to assess for slow, progressive neurologic involvement | Monitor 1x/yr even when metabolic control is optimal, especially in children age 12 yrs. Perform MRI/MRS in consultation w/neurologist. |
Source: GeneReviews — "Hyperornithinemia-Hyperammonemia-Homocitrullinuria Syndrome"
Disease patterns and progression |
12 |
15% |
Testing and diagnosis research | 11 | 14% |
Laboratory research | 8 | 10% |
Patient case studies | 6 | 8% |
Clinical study results | 3 | 4% |
New treatment approaches | 2 | 3% |
Other research | 1 | 1% |
Morales A (2026). [PMID: 29493987](https://pubmed.ncbi.nlm.nih.gov/29493987/). *Unknown Journal*. [Review / Meta-Analysis]
Nimmana BK (2026). [PMID: 32491436](https://pubmed.ncbi.nlm.nih.gov/32491436/). *Unknown Journal*. [Review / Meta-Analysis]
Donovan K (2026). [PMID: 30725942](https://pubmed.ncbi.nlm.nih.gov/30725942/). *Unknown Journal*. [Review / Meta-Analysis]
Gropman A (2026). [PMID: 42025243](https://pubmed.ncbi.nlm.nih.gov/42025243/). *Mol Genet Metab*. [Review / Meta-Analysis]
Bisht S (2026). [PMID: 29493985](https://pubmed.ncbi.nlm.nih.gov/29493985/). *Unknown Journal*. [Review / Meta-Analysis]
Gemici Karaaslan B (2025). [PMID: 39957310](https://pubmed.ncbi.nlm.nih.gov/39957310/). *J Inherit Metab Dis*. [Review / Meta-Analysis]
Siri B (2025). [PMID: 39776112](https://pubmed.ncbi.nlm.nih.gov/39776112/). *Journal of inherited metabolic disease*. [Diagnostic / Biomarker]
Kido J (2025). [PMID: 40464331](https://pubmed.ncbi.nlm.nih.gov/40464331/). *Pediatrics international : official journal of the Japan Pediatric Society*. [Review / Meta-Analysis]
Musunuru K (2025). [PMID: 40373211](https://pubmed.ncbi.nlm.nih.gov/40373211/). *The New England journal of medicine*. [Case Report / Case Series]
Hajati R (2025). [PMID: 41402828](https://pubmed.ncbi.nlm.nih.gov/41402828/). *BMC Med Genomics*. [Diagnostic / Biomarker]
AI-curated news mentioning urea cycle disorder or inherited hyperammonemia
Updated Aug 20, 2026
New research explores human cell-based models for studying the urea cycle, focusing on gene regulation and ureagenesis. These models aim to enhance disease modeling and therapeutic development for urea cycle disorders.
The federal agency ARPA-H earmarked $43 million for Philadelphia researchers to advance gene therapies for rare diseases. Among the recipients: gene therapy pioneer Jim Wilson and the Baby KJ team. » READ MORE: CHOP and Penn treated an infant with a rare disease by editing his genes · The funding will expand their work and bring in another CHOP researcher, Lindsey George, who develops gene therapies for bleeding disorders. » READ MORE: Feds award $22 million to Penn spinout Linnaeus Therapeutics to advance anti-aging drug · The CHOP team will focus on building a scalable gene-editing platform that can be used to treat a variety of infants and children. Their initial focus is on liver-related genetic diseases, ranging from urea cycle disorders to blood clotting diseases. “Essentially it’s the same drug, whether or not you’re targeting a genetic variant that causes a rare metabolic disease or a genetic variant that causes a rare coagulation disorder,” Ahrens-Nicklas said. The U.S. government has awarded Children’s Hospital of Philadelphia $39 million to develop a scalable platform for treating rare genetic, liver-related diseases in infants and children. The federal Advanced Research Projects Agency for Health (ARPA-H) also announced this week another $4 million for local gene therapy pioneer Jim Wilson to design gene therapies using AI at his University of Pennsylvania spinout, GEMMABio. Wilson founded academia’s first gene therapy program back in 1993 as a professor at Penn. He left in 2024 to spin out biotech start-ups dedicated to tackling rare diseases with genetic medicines.
The federal agency ARPA-H earmarked $43 million for Philadelphia researchers to advance gene therapies for rare diseases. Among the recipients: gene therapy pioneer Jim Wilson and the Baby KJ team. » READ MORE: CHOP and Penn treated an infant with a rare disease by editing his genes · The funding will expand their work and bring in another CHOP researcher, Lindsey George, who develops gene therapies for bleeding disorders. » READ MORE: Feds award $22 million to Penn spinout Linnaeus Therapeutics to advance anti-aging drug · The CHOP team will focus on building a scalable gene-editing platform that can be used to treat a variety of infants and children. Their initial focus is on liver-related genetic diseases, ranging from urea cycle disorders to blood clotting diseases. “Essentially it’s the same drug, whether or not you’re targeting a genetic variant that causes a rare metabolic disease or a genetic variant that causes a rare coagulation disorder,” Ahrens-Nicklas said. The U.S. government has awarded Children’s Hospital of Philadelphia $39 million to develop a scalable platform for treating rare genetic, liver-related diseases in infants and children. The federal Advanced Research Projects Agency for Health (ARPA-H) also announced this week another $4 million for local gene therapy pioneer Jim Wilson to design gene therapies using AI at his University of Pennsylvania spinout, GEMMABio. Wilson founded academia’s first gene therapy program back in 1993 as a professor at Penn. He left in 2024 to spin out biotech start-ups dedicated to tackling rare diseases with genetic medicines.
A recent study highlights the identification of a rare proximal urea cycle disorder in adults, triggered by an ammonia storm. This discovery may lead to improved diagnosis and management strategies for affected individuals.
Ultragenyx's gene therapy DTX301 successfully reduced ammonia levels by 18% in patients with a rare urea cycle disorder at 36 weeks, meeting one of the co-primary endpoints in its phase 3 trial. This promising result comes amid challenges for the company, including recent layoffs and a class-action lawsuit.